Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)

Innate Pharma has reported Current Deferred Revenue for 9 years, with the latest figure at $3.3 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue rose 399.57% year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2025 stood at $3.3 million (up 399.57% YoY), and the FY2025 full-year result was $3.3 million, up 399.57% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $3.3 million, up from $637293.3 in the prior quarter.
• The five-year high for Current Deferred Revenue was $14.3 million in Q4 2021, with the low at $637293.3 in Q2 2025.
• Historically, Current Deferred Revenue has averaged $6.3 million across 5 years, with a median of $5.9 million in 2023.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue plunged 99.97% — and 2025, when it soared 399.57%.
• Innate Pharma's Current Deferred Revenue stood at $14.3 million in 2021, then tumbled by 53.2% to $6.7 million in 2022, then decreased by 5.71% to $6.3 million in 2023, then plunged by 89.57% to $658254.8 in 2024, then soared by 399.57% to $3.3 million in 2025.
• The last three Current Deferred Revenue figures came in at $3.3 million (Q4 2025), $637293.3 (Q2 2025), and $658254.8 (Q4 2024), per Business Quant data.